GlassScriptPhysician profile
Andrea Brown Stringfellow
NPI 1285046110
$4,688.09
in general payments reported to CMS, 2019-2025
33 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $762 · 2022: $692 · 2023: $769 · 2024: $1,372 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,139 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,139.15 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $888.84 | 2021-2025 | |
| Novo Nordisk INC | $728.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $348.22 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $326.70 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $309.41 | 2024-2025 | Rexulti |
| Pfizer INC. | $299.68 | 2021-2024 | |
| Amgen INC. | $223.89 | 2021-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.42 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $189.14 | 2021-2024 | |
| Daiichi Sankyo INC. | $120.82 | 2022 | |
| Glaxosmithkline, LLC. | $115.47 | 2021-2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $113.86 | 2021-2025 | Trintellix |
| Dexcom, INC. | $112.32 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $94.99 | 2023 | |
| Exact Sciences Corporation | $83.15 | 2023-2025 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $70.86 | 2025 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.51 | 2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $56.95 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.27 | 2022-2025 | Xifaxan |
| Corcept Therapeutics | $40.72 | 2023 | Korlym |
| Azurity Pharmaceuticals, INC. | $36.52 | 2023 | Edarbi |
| Merck Sharp & Dohme LLC | $35.54 | 2021-2023 | Proquad, Vaxneuvance, Gardasil 9 |
| Ultragenyx Pharmaceutical INC. | $25.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.76 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.09 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.81 | 2021 | |
| Atland Pharmaceuticals, LLC | $17.49 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Athena Bioscience, LLC | $15.62 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.45 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.52 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.31 | 2022 | |
| Corium, LLC | $11.45 | 2023 | Azstarys |
| Phathom Pharmaceuticals, INC. | $11.26 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Stringfellow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.